学术周报 · IF≥10
眼科领域文献阅读汇编
2026年第44周 (2026-10-31) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| JAMA ophthalmology | 2 | IF 10.5 |
| Science advances | 1 | IF 13.9 |
| Nature medicine | 1 | IF 52.5 |
| Progress in retinal and eye research | 1 | IF 16.2 |
| JAMA dermatology | 1 | IF 10.9 |
| Pharmacological research | 1 | IF 12.2 |
| Journal of hazardous materials | 1 | IF 10.6 |
| Smart medicine | 1 | IF 12.8 |
| Autophagy | 1 | IF 18.6 |
| Advanced healthcare materials | 1 | IF 11.0 |
1影像与人工智能 (4篇)
临床研究 (3篇)
Despite their considerable promise, many current medical foundation models remain modality specific and lack transparent reasoning, limiting clinical adoption. To address this gap, we introduce Explainable Vision Language Foundation Model for Medicine (EVLF-FM), a multimodal vision language foundation model that combines broad diagnostic capabilities with fine-grained explainability. The development and testing of EVLF-FM encompassed more than 1.3 million total samples from 18 global datasets across 10 imaging modalities related to six clinical specialties: dermatology, hepatology, ophthalmology, pathology, pulmonology and radiology. External validation employed 13,443 independent test samples from 17 additional datasets across 10 imaging modalities. EVLF-FM supports disease diagnosis, visual question answering and pixel-level visual grounding with reasoning capabilities. In internal validation for disease diagnostics, EVLF-FM achieved the highest average accuracy, 0.895, outperforming leading generalist and specialist models. In medical visual grounding, EVLF-FM also achieved reasonable performance across nine modalities with average accuracy at 0.5 intersection over union (Acc@0.5) of 0.842. External testing further confirmed consistent zero-shot and few-shot performance, with competitive F1 scores despite a smaller model size. A hybrid training strategy combining supervised and visual reinforcement fine-tuning enables EVLF-FM to generate clinically interpretable explanations aligned with visual evidence. Human evaluation of these reasoning outputs using the S.C.O.R.E. framework yielded a high overall mean score of 4.25/5, supporting their clinical interpretability. Current limitations include the need for additional validation across diverse healthcare settings. Prospective clinical studies are required to evaluate the safety, effectiveness and clinical utility of EVLF-FM before routine clinical deployment.
中文摘要:当前不少医学基础模型虽具潜力,却仍局限于单一模态,且缺乏透明推理,限制了临床采用。为弥补这一缺口,我们提出可解释医学视觉语言基础模型 EVLF-FM,将较广的诊断能力与细粒度可解释性结合。EVLF-FM 的开发与测试覆盖 18 个全球数据集、超过 130 万样本,涉及皮肤科、肝病科、眼科、病理科、呼吸科和放射科六个临床专科的 10 种成像模态。外部验证使用来自另外 17 个数据集的 13,443 份独立测试样本,覆盖 10 种成像模态。EVLF-FM 支持疾病诊断、视觉问答和像素级视觉定位,并具备推理能力。疾病诊断的内部验证中,EVLF-FM 取得最高平均准确率 0.895,优于领先的通用模型和专科模型。医学视觉定位中,EVLF-FM 在九种模态上表现合理,平均准确率即交并比 0.5 下的准确率为 0.842。外部测试进一步确认零样本和少样本性能稳定,尽管模型规模较小,F1 分数仍具竞争力。监督学习与视觉强化微调结合的混合训练策略,使 EVLF-FM 能生成与视觉证据一致的临床可解释说明。使用 S.C.O.R.E. 框架对这些推理输出进行人工评价,总体平均分达 4.25/5,支持其临床可解释性。当前局限包括仍需在不同医疗环境中开展更多验证。在常规临床部署前,需开展前瞻性临床研究评估 EVLF-FM 的安全性、有效性和临床效用。
Tamoxifen can cause retinal toxicity and vision loss, yet no formal screening guideline exists in the US. To characterize ophthalmic use after tamoxifen initiation, identify predictors, and compare 12-month use between those with breast cancer taking tamoxifen and those taking aromatase inhibitors. This was a retrospective cohort study conducted May to June 2026 using All of Us data with 365-day minimum follow-up. The setting was a US multisite research program. Participants included adults with a first tamoxifen prescription recorded in All of Us, excluding those taking hydroxychloroquine. The comparator included those with breast cancer taking aromatase inhibitors. Tamoxifen or aromatase inhibitor initiation. The primary outcome was any ophthalmic encounter within 12 months, identified from eye examination, retinal procedure, and eye visit codes. Retinal optical coherence tomography (OCT) or fundus photography was secondary. Logistic regression assessed predictors and compared treatment groups after adjustment for demographics, preexisting conditions, preindex health care use, region, and initiation year. Among 2327 individuals taking tamoxifen (mean [SD] age, 53.8 [10.6] years; 2232 [95.9%] female), 162 (7.0%) had an ophthalmic encounter within 12 months, and 39 (1.7%) underwent retinal OCT or fundus photography. Among participants with preexisting glaucoma or diabetic retinopathy, 22 of 88 (25.0%) had an encounter vs 140 of 2239 (6.3%) without either condition (difference, 18.7 percentage points; 95% CI, 10.8-28.8 percentage points; P < .001). Preexisting glaucoma (adjusted odds ratio [aOR], 3.87; 95% CI, 2.12-7.06; P < .001), greater preindex health care use (aOR, 1.43; 95% CI, 1.24-1.63; P < .001), and older age (aOR per 10-year increase, 1.21; 95% CI, 1.04-1.42; P = .02) were associated with greater use. Among participants with breast cancer, 126 of 1886 individuals taking tamoxifen (6.7%) had an encounter vs 240 of 2809 individuals taking aromatase inhibitors (8.5%; difference, -1.9 percentage points; 95% CI, -3.4 to -0.3 percentage points; P = .02). After adjustment, tamoxifen use was not associated with greater ophthalmic use (aOR, 1.10; 95% CI, 0.85-1.42; P = .46). Results of this cohort study suggest that ophthalmic use after tamoxifen initiation was uncommon, and retinal-specific testing was rare. Tamoxifen use was not associated with greater adjusted 12-month use than aromatase inhibitor use. Additional evidence on retinopathy incidence, natural history, screening strategies, and clinical benefit is needed to inform guidance.
中文摘要:他莫昔芬可导致视网膜毒性和视力丧失,但美国尚无正式的筛查指南。研究旨在描述他莫昔芬起始后的眼科使用情况、识别预测因素,并比较服用他莫昔芬的乳腺癌患者与服用芳香化酶抑制剂者12个月内的眼科使用。这是一项回顾性队列研究,于2026年5月至6月开展,使用All of Us数据,最低随访365天。研究设置美国多中心研究项目。参与者为All of Us中记录首次他莫昔芬处方的成人,排除使用羟氯喹者。对照组成员为服用芳香化酶抑制剂的乳腺癌患者。暴露为他莫昔芬或芳香化酶抑制剂起始。主要结局为12个月内任何眼科就诊,依据眼科检查、视网膜操作和眼科就诊代码识别。视网膜光学相干断层扫描(OCT)或眼底照相为次要结局。采用logistic回归评估预测因素,并在校正人口学特征、既往疾病、索引前医疗服务使用、地区和起始用药年份后比较治疗组。2327名服用他莫昔芬者(平均[SD]年龄53.8[10.6]岁;2232[95.9%]女性)中,162人(7.0%)在12个月内有过眼科就诊,39人(1.7%)接受过视网膜OCT或眼底照相。在既存青光眼或糖尿病视网膜病变的参与者中,88人中有22人(25.0%)有眼科就诊,而无这两种情况者2239人中有140人(6.3%)有就诊(差异18.7个百分点;95% CI 10.8-28.8个百分点;P<.001)。既存青光眼(校正比值比[aOR] 3.87;95% CI 2.12-7.06;P<.001)、索引前医疗服务使用较多(aOR 1.43;95% CI 1.24-1.63;P<.001)和年龄较大(每增加10岁aOR 1.21;95% CI 1.04-1.42;P=.02)与更高的眼科使用相关。在乳腺癌参与者中,服用他莫昔芬者1886人中有126人(6.7%)有眼科就诊,服用芳香化酶抑制剂者2809人中有240人(8.5%;差异-1.9个百分点;95% CI -3.4至-0.3个百分点;P=.02)。校正后,他莫昔芬使用与更高的眼科使用无关(aOR 1.10;95% CI 0.85-1.42;P=.46)。这项队列研究结果提示,他莫昔芬起始后的眼科使用不常见,视网膜特异性检查罕见。他莫昔芬使用与芳香化酶抑制剂使用相比,校正后12个月眼科使用并无增加。仍需关于视网膜病变发生率、自然史、筛查策略和临床获益的更多证据以指导指南。
Whether a retinal artificial intelligence (AI) risk score reclassifies SCORE2 cardiovascular risk stratification in statin-naive adults across the ESC/EAS statin-indication boundary is uncertain. We evaluated the retinal AI risk score for 10-year atherosclerotic cardiovascular disease (ASCVD) prediction. In 40,672 statin-naive UK Biobank participants (aged 40-69, without diabetes), cardiovascular risk categories and treatment recommendation status (Class I or IIa vs neither) were defined using the 2025 ESC/EAS focused-update framework. Cox models estimated hazard ratios (HRs) adjusted for SCORE2 or for established risk factors. The incremental predictive value of adding the retinal AI risk score to SCORE2 was evaluated using 10-fold cross-validation. Over a 10.0-year median follow-up (914 ASCVD events), the very high retinal AI risk group independently predicted ASCVD (SCORE2-adjusted HR 2.32 vs low risk; p<0.001). Adding the retinal AI risk score to SCORE2 reclassified risk across the ESC/EAS statin-indication boundary (statin-eligibility NRI [net reclassification improvement] 0.012, p<0.001); reclassification was statistically significant but modest (continuous NRI 0.445, p<0.001), without C-index or net-benefit gain. In the statin-indicated subgroup, retinal AI risk groups further stratified risk (SCORE2-adjusted HR 2.16; p<0.001). Statin-not-indicated participants in the high or very high retinal AI risk groups had numerically similar observed 10-year risk to all statin-indicated, untreated participants (p=0.758). There was no evidence of effect modification by clinically detectable retinal disorder (interaction p=0.93). Incremental value was greater in women than men (sex interaction p<0.001). Adding the retinal AI risk score to SCORE2 produced modest bidirectional risk reclassification across the ESC/EAS statin-indication boundary; these findings warrant prospective validation.Abstract word count: 250 words.
中文摘要:视网膜人工智能(AI)风险评分能否在未使用他汀的成人中、跨越ESC/EAS他汀适应证边界重新分类SCORE2心血管风险尚不确定。我们评估了视网膜AI风险评分对10年动脉粥样硬化性心血管疾病(ASCVD)的预测价值。在40,672名未使用他汀的UK Biobank参与者(40-69岁,无糖尿病)中,依据2025 ESC/EAS focused-update框架定义心血管风险类别和治疗推荐状态(I类或IIa类 vs 两者均无)。Cox模型估计经SCORE2或既定危险因素校正的风险比。采用10折交叉验证评估将视网膜AI风险评分加入SCORE2的增量预测价值。中位随访10.0年(914例ASCVD事件),视网膜AI风险极高组独立预测ASCVD(较低风险组,SCORE2校正HR 2.32;p<0.001)。将视网膜AI风险评分加入SCORE2可在ESC/EAS他汀适应证边界上重新分类风险(他汀资格NRI 0.012,p<0.001);重分类有统计学意义但幅度有限(连续NRI 0.445,p<0.001),C指数或净获益无增益。在有他汀适应证的亚组中,视网膜AI风险组进一步分层风险(SCORE2校正HR 2.16;p<0.001)。无他汀适应证的参与者中,视网膜AI高风险或极高风险组的观察10年风险与所有有他汀适应证但未治疗的参与者数值相近(p=0.758)。无证据显示临床可检测视网膜疾病存在效应修饰(交互p=0.93)。女性中的增量价值大于男性(性别交互p<0.001)。将视网膜AI风险评分加入SCORE2在ESC/EAS他汀适应证边界产生有限的双向风险重分类;这些发现需要前瞻性验证。
基础研究 (1篇)
Neurodegenerative diseases are difficult to detect during their pre-symptomatic stages, when intervention is most effective. Advances in wearable biosensors, artificial intelligence (AI), and neuroscience now enable continuous monitoring of brain-related physiological signals in real-world settings. However, progress in sensing technologies, signal analytics, and machine learning remains fragmented, limiting the biological specificity, robustness, and clinical translation of many digital biomarkers. This review presents an integrated framework that links molecular pathology and neural circuit dysfunction to sensor-detectable digital phenotypes across sleep, autonomic regulation, gait, speech, and ocular dynamics. We evaluate emerging wearable platforms, including bioelectric, optical, and neuromotor sensors, and discuss critical design considerations such as signal quality, user-centered form factors, and ultra-low-power edge AI systems. We further examine how self-supervised learning, federated AI, mechanistic modeling, and fairness-aware validation can improve biomarker reliability, interpretability, and generalizability. To facilitate clinical deployment, we introduce the Personalized Brain-Health Operating System (pBH-OS), a privacy-preserving reference architecture for scalable digital phenotyping. The framework maps conceptual layers to existing technologies while identifying key validation gaps. We also address practical challenges, including adherence, device dropout, informative missingness, regulatory compliance, and accountability. Together, these advances provide a pathway toward biologically grounded and regulation-ready systems capable of identifying neurodegenerative risk years before clinical symptom onset.
中文摘要:神经退行性疾病在症状出现前阶段难以检出,而这一阶段干预最有效。可穿戴生物传感器、人工智能与神经科学的进展,使在真实环境中连续监测脑相关生理信号成为可能。传感技术、信号分析与机器学习的发展仍较分散,限制了许多数字生物标志物的生物学特异性、稳健性与临床转化。综述提出一个整合框架,将分子病理与神经环路功能障碍同睡眠、自主调节、步态、言语和眼动动力学中可被传感器检出的数字表型联系起来。我们评估新兴可穿戴平台,包括生物电、光学与神经运动传感器,并讨论信号质量、以用户为中心的外形设计和超低功耗边缘人工智能系统等关键设计问题。自监督学习、联邦人工智能、机制建模和公平性感知验证可提升生物标志物的可靠性、可解释性与泛化能力。为促进临床部署,我们介绍个性化脑健康操作系统(pBH-OS),一种保护隐私、可扩展数字表型分析的参考架构。该框架将概念层映射到现有技术,同时指出关键验证缺口。我们还讨论依从性、设备脱落、信息性缺失、监管合规与责任归属等实际挑战。这些进展共同指向一条路径,使系统具备生物学基础并满足监管要求,能够在临床症状出现前数年识别神经退行性疾病风险。
2视网膜疾病 (4篇)
基础研究 (4篇)
Mitochondrial dysfunction drives diseases, including ischemia-reperfusion injury, neurodegenerative disorders, cardiovascular disease, metabolic syndrome, and inflammation. Conventional mitochondria-targeted strategies offer only partial rescue and are insufficient for severe, irreversible damage. Mitochondrial transplantation (MT)-the delivery of exogenously isolated functional mitochondria to injured cells-has emerged as a promising therapeutic strategy that directly restores mitochondrial bioenergetic function and may subsequently modify the tissue microenvironment. This Review examines the entire MT pipeline, from mitochondrial source selection, isolation and preservation, to in vivo delivery strategies. We critically examine the multiple mechanisms underlying MT's therapeutic efficacy, including cellular uptake and intracellular integration, energy restoration and metabolic reprogramming, redox rebalancing, remodeling of mitochondrial quality control (fusion/fission, mitophagy, biogenesis), and immunomodulation. We summarize preclinical and clinical applications across multiple organ systems-heart, nervous system, liver, kidney, lung, skeletal muscle, retina-as well as in oncology and aging. We analyze five major translational bottlenecks: the lack of standardized manufacturing protocols, undefined dose-response relationships, immunogenicity and long-term safety uncertainties, the decisive impact of mitochondrial heterogeneity, and regulatory ambiguity. We outline future directions-mechanistic deepening, engineered target delivery, individualized mitochondrial medicine, combinatorial regimens, and a phased clinical roadmap. MT is not merely energy supplementation; it may reshape cellular metabolism, quality control networks, and immune microenvironments, representing a shift from pharmacological modulation of mitochondrial function toward organelle replacement strategies. Despite challenges, these advances may facilitate individualized mitochondrial therapies as a proposed future direction.
中文摘要:线粒体功能障碍驱动多种疾病,包括缺血再灌注损伤、神经退行性疾病、心血管疾病、代谢综合征和炎症。传统线粒体靶向策略只能部分挽救,对严重且不可逆损伤不足。线粒体移植(MT)是将外源分离的功能性线粒体递送至受损细胞,已成为有前景的治疗策略,可直接恢复线粒体生物能量功能,并可能随后改变组织微环境。本综述考察MT全流程,从线粒体来源选择、分离与保存到体内递送策略。批判性分析MT疗效的多重机制,包括细胞摄取与胞内整合、能量恢复与代谢重编程、氧化还原再平衡、线粒体质量控制重塑(融合/分裂、线粒体自噬、生物发生)以及免疫调节。总结心脏、神经系统、肝脏、肾脏、肺、骨骼肌、视网膜等多器官系统以及肿瘤学和衰老领域的临床前与临床应用。分析五个主要转化瓶颈:缺乏标准化生产方案、剂量反应关系未明、免疫原性与长期安全性不确定、线粒体异质性的决定性影响、监管模糊。提出未来方向:机制深化、工程化靶向递送、个体化线粒体医学、联合方案和分阶段临床路线图。MT不仅是能量补充,还可能重塑细胞代谢、质量控制网络和免疫微环境,代表从线粒体功能的药理学调节转向细胞器替代策略。尽管存在挑战,这些进展可能促进个体化线粒体治疗成为未来方向。
Acid mine drainage (AMD) from karst sulfide mines threatens regional groundwater security, yet water-rock-pollutant coupling across heterogeneous runoff media remains poorly understood. Using hydrogeological, hydrochemical and isotopic data, we examined four water types-tailings-pond water (M-type), fracture-spring and conduit water (S-type, G-type) and surface river water (R-type)-along fracture-conduit runoff zones in an AMD-affected karst watershed during the August 2024 wet season. All waters were circumneutral to weakly alkaline, carbonate-neutralized AMD-affected waters, not acidic leachate. Isotopes (δ²H-H₂O, δ¹⁸O-H₂O, δ³⁴S-SO₄ and δ¹⁸O-SO₄) and hydrochemistry showed that M water was dominated by sulfuric-acid dissolution, S-type water by mixed carbonic-sulfuric-acid dissolution, R-type water by coexisting multi-acid dissolution and G-type water by carbonic-acid dissolution. S-type water showed stronger apparent bidirectional AMD buffering than R/G-type water, although dilution and immobilization could not be distinguished. Isotope patterns were consistent with preferential bacterial sulfate reduction (BSR) in fractures, one of several interpretations pending microbiological verification. Sulfide oxidation elevated dissolved metals in M-type water; dilution reduced them downstream in R-type water. S-type water likely attenuated metals through carbonate buffering and weakly reducing conditions, with a possible unverified BSR contribution; G-type water buffered mainly through carbonate dissolution. These findings support karst AMD prevention and control.
中文摘要:岩溶硫化物矿山的酸性矿山废水(AMD)威胁区域地下水安全,但异质径流介质中的水—岩—污染物耦合仍认识不足。利用水文地质、水化学和同位素数据,我们考察了2024年8月湿季受AMD影响的岩溶流域沿裂隙—管道径流带的四类水体:尾矿库水(M型)、裂隙泉水和管道水(S型、G型)以及地表河水(R型)。所有水体均为近中性至弱碱性、受碳酸盐中和的AMD影响水体,而非酸性渗滤液。同位素(δ²H-H₂O、δ¹⁸O-H₂O、δ³⁴S-SO₄和δ¹⁸O-SO₄)与水化学表明,M型水以硫酸溶解为主,S型水以碳酸—硫酸混合溶解为主,R型水以多酸共存溶解为主,G型水以碳酸溶解为主。S型水表现出比R型水和G型水更强的表观双向AMD缓冲能力,但稀释与固定作用无法区分。同位素特征与裂隙中优先发生细菌硫酸盐还原(BSR)一致,这只是若干解释之一,尚待微生物学验证。硫化物氧化提高了M型水中溶解态金属含量;稀释使R型水下游金属含量降低。S型水可能通过碳酸盐缓冲和弱还原条件衰减金属,并可能有尚未验证的BSR贡献;G型水主要通过碳酸盐溶解实现缓冲。这些发现支持岩溶区AMD的防控。
The retinal pigment epithelium (RPE) sustains lifelong proteostasis under chronic stress, yet how post-mitotic cells activate macroautophagy/autophagy when canonical kinase pathways suppress it remains unresolved. Here we demonstrate that AKT1 (protein kinase B alpha), drives autophagy through a non-canonical transcriptional mechanism triggered by isoform imbalance. In RPE and age-related macular degeneration (AMD) models, AKT2 (protein kinase B beta) hyperactivation destabilizes MTORC2 (mechanistic target of rapamycin complex 2) and engages RPS6KB/S6K (ribosomal protein S6 kinase beta) -mediated IRS-1 (insulin Receptor Substrate 1) inhibition, creating a feedforward autophagic arrest. Compensatory AKT1 activation via MTORC2 phosphorylates TERT (telomerase reverse transcriptase) at serine 824, driving nuclear translocation that is independent of telomere maintenance. In the nucleus, TERT assembles with FOXO3 (forkhead Box O3) and MYC (MYC proto-oncogene, bHLH transcription factor) into a tripartite transcriptional complex that occupies the EIF2AK3/PERK promoter (eukaryotic translation initiation factor 2-alpha kinase 3/ protein kinase R-like endoplasmic reticulum kinase), enabling EIF2AK3 transcriptional activation. This activity converts the unfolded protein response from pro-apoptotic to cytoprotective: EIF2AK3-ATF4 (activating transcription factor 4) signaling promotes core autophagy machinery biogenesis and selective ERphagy through the receptors TEX264 (testis expressed 264) and CCPG1(cell cycle progression 1), which prevents pathological EIF2AK3 clustering and preserves tubular ER architecture in diseased RPE. Using C. elegans phosphorylation-deficient mutants, mouse models and AMD patient iPSC-RPE, we establish that AKT1-mediated TERT phosphorylation is an evolutionarily conserved prerequisite for FOXO/DAF-16 nuclear function and lysosomal homeostasis in post-mitotic cells, offering therapeutic potential through targeted pharmacologic inhibition of AKT2.Abbreviations: ACTB: actin, beta; AKT1: AKT serine/threonine kinase 1; AKT2: AKT serine/threonine kinase 2; ALP: autophagy-lysosomal pathway; AMD: age-related macular degeneration, ATF4: activating transcription factor 4; ATG3: autophagy related 3; ATG4B: autophagy related 4B cysteine peptidase; ATG7: autophagy related 7; CCPG1: cell cycle progression 1; CFH: complement factor H; C57BL/6J: C57 black 6J; DMSO: dimethyl sulfoxide; MYC: MYC proto-oncogene, bHLH transcription factor; EIF2A/eIF2α: eukaryotic translation initiation factor 2A; EIF2AK3/PERK: eukaryotic translation initiation factor 2 alpha kinase 3; ER: endoplasmic reticulum; ERN1/IRE-1α: endoplasmic reticulum to nucleus signaling 1; ERphagy: endoplasmic reticulum-selective autophagy; FOXO1: forkhead box O1; FOXO3: forkhead box O3; iPSC-RPE: induced pluripotent stem cell-derived retinal pigment epithelium; ITGB1/integrin β1: integrin subunit beta 1; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAPKAP1/SIN1: MAPK associated protein 1; MTOR: mechanistic target of rapamycin kinase; MTORC1: MTOR complex 1; MTORC2: MTOR complex 2; PBS: phosphate-buffered saline; PI3K: phosphoinositide 3-kinase; RICTOR: RPTOR independent companion of MTOR complex 2; RPE: retinal pigment epithelium; RPTOR: regulatory associated protein of MTOR complex 1; SQSTM1/p62: sequestosome 1; TERT: telomerase reverse transcriptase; TEX264: testis expressed 264, ER-phagy receptor; UPR: unfolded protein response; VCL: vinculin; WT: wild type.
中文摘要:视网膜色素上皮(RPE)在慢性应激下维持终身蛋白稳态,但分裂后细胞在经典激酶通路抑制自噬时如何激活巨自噬/自噬仍不清楚。我们发现AKT1(蛋白激酶B α)通过异构体失衡触发的非经典转录机制驱动自噬。在RPE与年龄相关性黄斑变性(AMD)模型中,AKT2(蛋白激酶B β)过度活化使MTORC2(雷帕霉素机制靶点复合物2)失稳,并启动RPS6KB/S6K(核糖体蛋白S6激酶β)介导的IRS-1(胰岛素受体底物1)抑制,形成前馈性自噬阻滞。经MTORC2的代偿性AKT1活化在丝氨酸824位点磷酸化TERT(端粒酶逆转录酶),驱动不依赖端粒维持的核转位。在核内,TERT与FOXO3(叉头框O3)及MYC(MYC原癌基因,bHLH转录因子)组装成三联转录复合物,占据EIF2AK3/PERK启动子(真核翻译起始因子2α激酶3/蛋白激酶R样内质网激酶),促成EIF2AK3转录激活。该活性将未折叠蛋白反应由促凋亡转为细胞保护性:EIF2AK3-ATF4(激活转录因子4)信号促进核心自噬机器生成,并通过受体TEX264(睾丸表达264)与CCPG1(细胞周期进程1)实现选择性内质网自噬,防止病理性EIF2AK3聚集并维持病变RPE中的管状内质网结构。利用秀丽隐杆线虫磷酸化缺陷突变体、小鼠模型与AMD患者iPSC-RPE,我们确立AKT1介导的TERT磷酸化是分裂后细胞中FOXO/DAF-16核功能与溶酶体稳态的进化保守前提,并提示通过靶向药物抑制AKT2具有治疗潜力。
Elevated levels of IL-8 have been detected in the vitreous samples of patients with diabetic retinopathy. However, its role in retinal neovascularization remains unknown. We hypothesized that IL-8 and its murine orthologues, CXCL1/2, are key mediators of oxygen-induced retinopathy (OIR)-driven retinal angiogenesis. To this end, we found that VEGFA stimulates CXCL1/2 and their receptor CXCR2 expression in mouse retinal microvascular endothelial cells (MRMVECs) in a time-dependent manner. Recombinant CXCL1/2 induced MRMVEC migration, proliferation, sprouting, and tube formation alone and in combination. Neutralizing CXCL1/2 or CXCR2 antibodies (Abs) attenuated the angiogenic effects of CXCL1/2 as well as VEGFA. In line with these observations in mice, VEGFA induced IL-8 and its receptor CXCR2 expression in human retinal microvascular endothelial cells (HRMVECs), and neutralizing IL-8 or CXCR2 Abs suppressed their angiogenic effects. Furthermore, OIR induced CXCL1/2 and CXCR2 expression in the mouse retina in vivo, and blockade of their function using their neutralizing Abs reduced retinal neovascularization. Mechanistically, depletion of ATF6 or GRP78 levels abrogated VEGFA-induced CXCL1/2 and CXCR2 expression in MRMVECs and IL-8 and CXCR2 expression in HRMVECs in vitro and OIR-induced CXCL1/2 and CXCR2 expression in vivo in mice. Furthermore, silencing VEGFR2 or VEGFR3 levels inhibited VEGFA/OIR-induced ATF6-GRP78 activation and their downstream CXCL1/2, IL-8 and CXCR2 expression both in vitro and in vivo. Together, these findings identify IL-8 as potential therapeutic target for treating retinal neovascular diseases.
中文摘要:在糖尿病视网膜病变患者玻璃体样本中检测到IL-8水平升高,但其在视网膜新生血管形成中的作用仍不清楚。我们假设IL-8及其小鼠同源物CXCL1/2是氧诱导视网膜病变(OIR)驱动视网膜血管生成的关键介质。为此,我们发现VEGFA以时间依赖方式刺激小鼠视网膜微血管内皮细胞(MRMVECs)中CXCL1/2及其受体CXCR2的表达。重组CXCL1/2单独及联合应用均可诱导MRMVEC迁移、增殖、出芽和管腔形成。中和CXCL1/2或CXCR2抗体可减弱CXCL1/2以及VEGFA的促血管生成效应。与小鼠观察一致,VEGFA诱导人视网膜微血管内皮细胞(HRMVECs)中IL-8及其受体CXCR2表达,中和IL-8或CXCR2抗体可抑制其促血管生成效应。此外,OIR在体内诱导小鼠视网膜CXCL1/2和CXCR2表达,使用中和抗体阻断其功能可减少视网膜新生血管。机制上,敲低ATF6或GRP78水平可消除VEGFA诱导的MRMVECs中CXCL1/2和CXCR2表达、HRMVECs中IL-8和CXCR2表达,以及小鼠体内OIR诱导的CXCL1/2和CXCR2表达。沉默VEGFR2或VEGFR3水平可抑制VEGFA/OIR诱导的ATF6-GRP78激活及其下游CXCL1/2、IL-8和CXCR2表达,体外和体内均如此。这些发现将IL-8确定为治疗视网膜新生血管疾病的潜在治疗靶点。
3葡萄膜炎与免疫 (2篇)
临床研究 (1篇)
Mucous membrane pemphigoid (MMP) is a chronic autoimmune blistering disease associated with progressive mucosal scarring and substantial morbidity. Prior studies have often reported remission rates in cohorts combining localized and multisite disease, with limited data on simultaneous remission across all involved sites in patients with multisite disease. To evaluate multisite complete remission (mCR) and site-specific treatment response patterns in patients with multisite MMP. This retrospective cohort study took place at a single tertiary dermatology and ophthalmology referral center at the University of Texas Southwestern Medical Center between January 1, 2013, and January 1, 2025. Patients with MMP confirmed by immunopathology, disease involving 2 or more anatomic sites, and 12 months posttreatment follow-up were included. The primary outcome was mCR, defined as concurrent complete remission across all involved sites regardless of therapy. Secondary outcomes included site-specific remission and relapse patterns, time to remission, and treatment-associated adverse events. Among 77 patients (55 [71%] female; median [IQR] age at diagnosis, 66 [59-72] years), 68 (88%) had high-risk disease involving ocular, laryngeal, esophageal, or anogenital sites. Oral disease was most common, present in 73 patients (95%), followed by ocular disease in 51 (66%) and nasal disease in 38 (49%). Thirty-five patients (45%) achieved mCR in a median (IQR) of 32.0 (20.7-55.3) months. Although all patients demonstrated improvement and 64 (83%) achieved CR at 1 or more sites, persistent oral and ocular diseases frequently prevented mCR. Relapses following site-level CR occurred in 28 of the 64 patients (44%), most frequently at the oral (18 of 28 patients [64%]) and ocular mucosa (14 of 28 patients [50%]); some patients experienced relapse at multiple sites. Rituximab-based regimens and Janus kinase inhibitor therapy were associated with high rates of improvement. Serious adverse events occurred most frequently with cyclophosphamide monotherapy and Janus kinase inhibitor therapy. In this cohort study, fewer than half of patients with multisite MMP achieved simultaneous multisite remission despite high rates of site-level response. Persistent oral and ocular diseases disproportionately limited global disease control, supporting a site-specific model of disease behavior and highlighting the need for standardized multisite remission outcomes in future studies.
中文摘要:黏膜类天疱疮(MMP)是一种慢性自身免疫性大疱性疾病,可导致进行性黏膜瘢痕形成和显著疾病负担。既往研究多在包含局限性与多部位病变的队列中报告缓解率,关于多部位病变患者所有受累部位同时缓解的数据有限。本研究评估多部位MMP患者的多部位完全缓解(mCR)及部位特异性治疗反应模式。该回顾性队列研究在德克萨斯大学西南医学中心单一三级皮肤科与眼科转诊中心开展,纳入时间为2013年1月1日至2025年1月1日。纳入经免疫病理确诊、病变累及2个及以上解剖部位且有治疗后12个月随访的患者。主要结局为mCR,定义为不论治疗方案如何,所有受累部位同时达到完全缓解。次要结局包括部位特异性缓解与复发模式、缓解时间及治疗相关不良事件。77例患者中(55例[71%]为女性;诊断时中位[IQR]年龄66[59-72]岁),68例(88%)为累及眼部、喉部、食管或肛门生殖器部位的高危疾病。口腔病变最常见,73例(95%),其次为眼部51例(66%)和鼻部38例(49%)。35例(45%)达到mCR,中位(IQR)时间为32.0(20.7-55.3)个月。所有患者均有改善,64例(83%)在1个及以上部位达到完全缓解,但持续存在的口腔和眼部病变常阻碍mCR。部位水平完全缓解后复发见于64例中的28例(44%),最常见于口腔黏膜(28例中18例[64%])和眼黏膜(28例中14例[50%]);部分患者在多个部位复发。以利妥昔单抗为基础的方案和Janus激酶抑制剂治疗与较高改善率相关。严重不良事件最常发生于环磷酰胺单药治疗和Janus激酶抑制剂治疗。该队列中,尽管部位水平反应率较高,不足一半的多部位MMP患者达到多部位同时缓解。持续的口腔和眼部病变对整体疾病控制造成不成比例的限制,支持疾病行为的部位特异性模型,并提示未来研究需要标准化的多部位缓解结局。
基础研究 (1篇)
Autoimmune uveitis (AU) is a leading cause of irreversible blindness driven by pathogenic T helper 17 (TH17) cell-mediated inflammation, yet current therapies are limited by efficacy and side effects, with immunometabolic mechanisms remaining poorly defined. By integrating single-cell RNA sequencing and multilayered metabolomic profiling in patients with AU and experimental AU models, we identified the lipid-sensing G protein-coupled receptor GPR183 as a key immunometabolic regulator in pathogenic CD4+ T cells. Upon activation, GPR183 modulates intracellular signaling via suppression of cyclic adenosine monophosphate-cAMP-dependent protein kinase activity and promotion of son-of-sevenless-dependent KRAS activation, which in turn elicits copper overload-induced mitochondrial oxidative stress, structural impairment, and metabolic rewiring toward glycolysis, thereby promoting TH17 cell pathogenicity. For clinical translation, virtual screening of Food and Drug Administration-approved drugs coupled with molecular docking and microscale thermophoresis validation identified fluvoxamine (FLV) as a direct GPR183 antagonist. In in vivo and in vitro uveitis and colitis models, FLV attenuated GPR183-KRAS signaling, dampened pathogenic TH17 cell responses, and alleviated tissue inflammation. These findings delineate a unique GPR183-KRAS-mitochondrial damage axis governing TH17-driven autoimmunity and support repurposing FLV as a translatable therapeutic approach for AU and other autoimmune inflammatory disorders.
中文摘要:自身免疫性葡萄膜炎(AU)是导致不可逆失明的主要原因,由致病性辅助性T细胞17(TH17)介导的炎症驱动,现有疗法受疗效和副作用限制,免疫代谢机制仍不清楚。通过整合AU患者和实验性AU模型的单细胞RNA测序与多层代谢组学分析,我们鉴定脂质感知G蛋白偶联受体GPR183是致病性CD4+ T细胞中的关键免疫代谢调控因子。激活后,GPR183通过抑制环磷酸腺苷-cAMP依赖性蛋白激酶活性、促进son-of-sevenless依赖的KRAS激活来调控细胞内信号,进而引发铜过载诱导的线粒体氧化应激、结构损伤和向糖酵解的代谢重编程,促进TH17细胞致病性。为临床转化,对FDA批准药物进行虚拟筛选,结合分子对接和微量热泳动验证,鉴定氟伏沙明(FLV)为GPR183直接拮抗剂。在体内和体外葡萄膜炎与结肠炎模型中,FLV减弱GPR183-KRAS信号,抑制致病性TH17细胞反应,减轻组织炎症。这些发现阐明GPR183-KRAS-线粒体损伤轴调控TH17驱动的自身免疫,支持将FLV重新定位为AU及其他自身免疫炎症性疾病的可转化治疗策略。
4青光眼 (1篇)
临床研究 (1篇)
Rural populations face disparities in eye care; therefore, understanding the utilization of structural imaging and visual field (VF) testing for glaucoma monitoring among rural compared with urban patients is important. To evaluate whether rural residence and sociodemographic factors are associated with patterns of VF testing and retinal nerve fiber layer (RNFL) optical coherence tomography (OCT) in patients with glaucoma. This retrospective longitudinal cohort study used data from the Sight Outcomes Research Collaborative (SOURCE) consortium, a multi-institutional repository of US academic ophthalmic clinical data, from May 2012 to January 2025. Included patients had at least 2 separate dates of glaucoma billing codes, at least 3 years of follow-up data, and at least 1 VF or RNFL OCT test. Rural vs urban residence, categorized by Rural-Urban Commuting Area codes. Primary outcomes were utilization frequency (tests per year) and regular monitoring (≥1 test every 18 months) for VF and RNFL OCT. Testing frequency was analyzed using multivariable negative binomial regression, and regular monitoring was analyzed using logistic regression adjusted for sociodemographic characteristics and baseline visual acuity. Among 48 196 patients, 45 843 (95.1%) lived in urban areas (25 613 [55.9%] female; mean [SD] age, 67.78 [12.71] years) and 2353 (4.9%) lived in rural areas (1272 [54.1%] female; mean [SD] age, 67.3 [12.03] years). Mean (SD) VF testing frequency was 0.91 (0.52) tests per year among rural patients and 0.91 (0.56) among urban patients; rural residence was not associated with regular VF monitoring (adjusted odds ratio [AOR], 0.95; 95% CI, 0.88-1.04; P = .28). Rural residence was associated with lower RNFL OCT frequency (mean [SD], 0.57 [0.45] vs 0.63 [0.47] tests per year; difference, -0.06 [95% CI, -0.08 to -0.04] tests per year; adjusted incidence rate ratio, 0.93 [95% CI, 0.88-0.98]; P = .004) and lower odds of regular RNFL OCT monitoring (AOR, 0.82; 95% CI, 0.74-0.90; P < .001). Medicaid insurance was associated with lower odds of regular monitoring with VF (AOR, 0.35; 95% CI, 0.30-0.40; P < .001) and RNFL OCT (AOR, 0.62; 95% CI, 0.52-0.74; P < .001). In this cohort study, rural residence was associated with lower utilization of RNFL OCT but not VF testing, while Medicaid insurance was associated with lower odds of monitoring for both modalities. The findings suggest that ophthalmologists should be aware that rural patients with glaucoma may require additional attention to continuity of structural imaging.
中文摘要:农村人群在眼科诊疗中存在差异,因此了解农村与城市青光眼患者在监测中利用结构成像和视野(VF)检查的情况很重要。评估农村居住地和社会人口学因素是否与青光眼患者的视野检查和视网膜神经纤维层(RNFL)光学相干断层扫描(OCT)模式相关。这项回顾性纵向队列研究使用Sight Outcomes Research Collaborative(SOURCE)联盟的数据,该联盟是美国学术眼科临床数据的多机构存储库,数据时间为2012年5月至2025年1月。纳入患者至少有2个不同日期的青光眼计费编码、至少3年随访数据,以及至少1次视野或RNFL OCT检查。农村与城市居住地按农村-城市通勤区(RUCA)编码分类。主要结局为视野和RNFL OCT的使用频率(每年检查次数)和规律监测(每18个月至少1次检查)。检查频率采用多变量负二项回归分析,规律监测采用logistic回归分析,并校正社会人口学特征和基线视力。在48 196例患者中,45 843例(95.1%)居住在城市(25 613例[55.9%]为女性;平均[SD]年龄67.78[12.71]岁),2 353例(4.9%)居住在农村(1 272例[54.1%]为女性;平均[SD]年龄67.3[12.03]岁)。农村患者视野检查频率的平均(SD)为每年0.91(0.52)次,城市患者为0.91(0.56)次;农村居住地与规律视野监测无关联(校正比值比[AOR]0.95;95%CI 0.88-1.04;P=.28)。农村居住地与较低的RNFL OCT检查频率相关(平均[SD]每年0.57[0.45]次对0.63[0.47]次;差异-0.06[95%CI -0.08至-0.04]次/年;校正发病率比0.93[95%CI 0.88-0.98];P=.004),并与较低的规律RNFL OCT监测几率相关(AOR 0.82;95%CI 0.74-0.90;P<.001)。医疗补助保险与较低的规律视野监测几率相关(AOR 0.35;95%CI 0.30-0.40;P<.001),也与较低的规律RNFL OCT监测几率相关(AOR 0.62;95%CI 0.52-0.74;P<.001)。在这项队列研究中,农村居住地与较低的RNFL OCT使用相关,但与视野检查使用无关;医疗补助保险则与两种监测方式的较低监测几率相关。结果提示,眼科医生应意识到农村青光眼患者可能需要额外关注结构成像的连续性。
5角膜与视网膜 (1篇)
基础研究 (1篇)
Three-dimensional bioprinting has emerged as a promising strategy for addressing major unmet needs in ophthalmology, including the global shortage of donor corneal tissue and the absence of restorative therapies for retinal degenerative disease. Advances in biomaterials, stem cell biology, and biofabrication have enabled increasingly sophisticated ocular constructs, ranging from engineered corneal grafts to multicellular retinal models that recapitulate key aspects of native tissue architecture. However, substantial challenges remain in reproducing the optical, mechanical, and biological functions required for clinical translation. This review critically evaluates the current state of corneal and retinal bioprinting through a framework organized around tissue target, fabrication modality, and intended application. Major bioprinting approaches, including extrusion-based, laser-assisted, drop-on-demand, and light-based technologies, are compared with respect to resolution, cell compatibility, scalability, and translational potential. Particular emphasis is placed on the engineering constraints governing construct fidelity, bioink design, tissue integration, and long-term functional performance. Current evidence suggests that corneal and retinal bioprinting have progressed along distinct translational trajectories. Corneal bioprinting has achieved encouraging preclinical outcomes, with selected approaches entering early clinical evaluation, whereas retinal bioprinting has generated highly informative disease models but remains at an earlier stage of translational development. Across both tissues, the field has increasingly shifted from reproducing individual cellular components toward reconstructing the biological interfaces and multicellular systems that underlie tissue function. Future progress will depend on establishing functional validation frameworks, reproducible manufacturing workflows, and standardized benchmarks to support the clinical development of vision-restoring bioprinted constructs.
中文摘要:三维生物打印已成为应对眼科重大未满足需求的有前景策略,包括全球供体角膜组织短缺以及视网膜退行性疾病缺乏修复性疗法。生物材料、干细胞生物学和生物制造技术的进展,使眼组织构建体日益精细,从工程化角膜移植物到可重现天然组织架构关键特征的多细胞视网膜模型。要在临床转化中重现所需的光学、力学和生物学功能仍存在显著挑战。该综述围绕组织靶点、制造方式和预期应用构建框架,批判性评估角膜与视网膜生物打印的现状。对挤出式、激光辅助式、按需滴落式和光基技术等主要生物打印方法,从分辨率、细胞相容性、可扩展性和转化潜力方面进行比较。重点讨论制约构建体保真度、生物墨水设计、组织整合和长期功能表现的工程约束。现有证据表明,角膜与视网膜生物打印沿不同的转化轨迹发展。角膜生物打印已取得令人鼓舞的临床前结果,部分方法进入早期临床评估;视网膜生物打印已产生信息丰富的疾病模型,但仍处于转化开发的较早阶段。在两种组织中,该领域正从复制单一细胞组分转向重建支撑组织功能的生物界面和多细胞系统。未来进展将取决于建立功能验证框架、可重复的制造流程和标准化基准,以支持恢复视力的生物打印构建体进入临床开发。
6白内障与屈光手术 (1篇)
基础研究 (1篇)
Ophthalmic engineering is defined by a rigorous set of constraints including the need for absolute optical clarity, precise viscoelasticity, and the ability to navigate formidable physiological barriers. Polymeric hydrogels have ascended as the quintessential material class to resolve these conflicts by leveraging their high content of water to create a seamless interface with native ocular tissues. This review critically examines the transition of these materials from passive structural substitutes to dynamic and stimulus-responsive systems. The molecular strategies required to balance mechanical robustness with biodegradation are dissected alongside the integration of responsive moieties that react to physiological cues. These principles are explored through cutting-edge clinical applications including suprachoroidal drug depots, bio-integrative tissue sealants, and closed-loop biosensing contact lenses. Finally, the discussion addresses the translational gap separating laboratory innovation from industrial manufacturing. By identifying persistent hurdles such as the inherent trade-off between long-term stability and transparency as well as sterilization compatibility, a strategic roadmap is outlined for the next generation of vision-restoring technologies.
中文摘要:眼科工程受严格约束,包括绝对光学透明性、精确黏弹性以及穿越复杂生理屏障的能力。聚合物水凝胶凭借高含水量与天然眼组织形成无缝界面,已成为解决这些矛盾的关键材料类别。该综述批判性审视这类材料从被动结构替代物向动态和刺激响应系统的转变。文中剖析平衡力学强度与生物降解所需的分子策略,并讨论对生理信号作出反应的响应性基团的整合。通过脉络膜上腔药物储库、生物整合性组织密封剂和闭环生物传感隐形眼镜等前沿临床应用探讨这些原理。最后讨论实验室创新与工业制造之间的转化差距。通过识别长期稳定性与透明性之间固有权衡以及灭菌兼容性等持续障碍,为下一代恢复视力技术勾勒战略路线图。